| TIME: | | | 11 a.m., Eastern standard time | |
| DATE: | | | April 23, 2020 | |
| PLACE: | | |
Anchiano Therapeutics Ltd., Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA 02139
Please note that in light of current circumstances and various restrictions that are being imposed because of COVID-19, it may become necessary to change the venue of the meeting. Any such change will be announced in a Form 8-K filed with the Securities and Exchange Commission.
|
|
Name
|
| |
Age
|
| |
Director Since
|
| |
Position
|
|
Mr. Dennison Veru(1) | | |
59
|
| |
2016
|
| |
Interim Chairman of the Board
|
|
Dr. Frank Haluska | | |
61
|
| |
2016
|
| |
Chief Executive Officer and Director
|
|
Ms. Ruth Alon(1)(2) | | |
68
|
| |
2017
|
| |
Director
|
|
Mr. Neil Cohen | | |
56
|
| |
N/A
|
| |
N/A
|
|
Mr. Ofer Gonen | | |
46
|
| |
2019
|
| |
Director
|
|
Mr. Reginald Hardy(2)(3) | | |
62
|
| |
2016
|
| |
Director
|
|
Mr. Isaac Kohlberg | | |
68
|
| |
2017
|
| |
Director
|
|
Mr. Stanislav Polovets | | |
56
|
| |
N/A
|
| |
N/A
|
|
| | |
Number of
Ordinary Shares Beneficially Owned |
| |
Percentage of
Outstanding Ordinary Shares |
| ||||||
Clal Biotechnology Industries Ltd.(1)
|
| | | | 9,307,662 | | | | | | 23.57% | | |
Shavit Capital Funds(2)
|
| | | | 8,868,546 | | | | | | 21.67% | | |
Access Industries Holdings LLC(3)
|
| | | | 15,829,397 | | | | | | 40.08% | | |
Edgewater Partner Holdings Ltd.(4)
|
| | | | 1,923,075 | | | | | | 5.18% | | |
Palisade Medical Equity I, LP(5)
|
| | | | 1,882,700 | | | | | | 5.07% | | |
| | |
Shares Beneficially
Owned |
| |||||||||
Name of Director, Director Nominee and Executive Officer
|
| |
Number
|
| |
Percentage(1)
|
| ||||||
Dr. Frank G. Haluska(2)
|
| | | | 1,852,499 | | | | | | 4.76% | | |
Jonathan Burgin(3)
|
| | | | 139,287 | | | | | | * | | |
Dr. David Kerstein(4)
|
| | | | 127,500 | | | | | | * | | |
Dr. Ron Knickerbocker(5)
|
| | | | 85,313 | | | | | | * | | |
Dr. Michal Gilon Ohev-Zion(6)
|
| | | | 48,014 | | | | | | * | | |
Sean Daly(7)
|
| | | | 34,073 | | | | | | * | | |
Salar Roshan
|
| | | | — | | | | | | — | | |
Ruth Alon(8)
|
| | | | 18,578 | | | | | | * | | |
Ofer Gonen(9)
|
| | | | — | | | | | | — | | |
Reginald L. Hardy(10)
|
| | | | 18,335 | | | | | | * | | |
Dr. Lawrence Howard(11)
|
| | | | 95,260 | | | | | | * | | |
Isaac T. Kohlberg(12)
|
| | | | 18,335 | | | | | | * | | |
Dennison T. Veru(13)
|
| | | | 2,001,035 | | | | | | 5.39% | | |
Neil Cohen(14)
|
| | | | 107,044 | | | | | | * | | |
Stanislav Polovets(15)
|
| | | | — | | | | | | — | | |
All directors, director nominees and executive officers as a group (14 persons)
|
| | | | 2,715,408 | | | | |
|
6.88%
|
| |
| | |
Year Ended December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
| | |
(Amounts in thousands)
|
| |||||||||
Audit fees(1)
|
| | | $ | 255 | | | | | $ | 187 | | |
Audit related fees(2)
|
| | | | 0 | | | | | | 0 | | |
Tax fees(3)
|
| | | | 3 | | | | | | 3 | | |
Other fees(4)
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | $ | 258 | | | | | $ | 190 | | |
Position
|
| |
Ratio to the average
overall cost of employment of all other Company employees (including the other Office Holders) |
| |
Ratio to the median
overall cost of employment of all other Company employees (including the other Office Holders) |
|
CEO
|
| |
4.553.04
|
| |
6.245.51
|
|
C-level Office Holders
|
| |
Not more than 3.592.00*
|
| |
Not more than 5.153.64*
|
|
Position
|
| |
CEO
|
| |
Israeli C-level
Office Holders |
| |
Non-Israeli C-level
Office Holders |
| |||||||||
Cost of Salary
|
| | | | USD 600K | | | | | | NIS 1,200K | | | | | | USD 570K | | |
Position
|
| |
CEO
|
| |
Israeli C-level
Office Holders |
| |
Non-Israeli C-level
Office Holders |
| |||||||||
Annual Bonus
|
| | | | 12 | | | | | | 10 | | | | | | 10 | | |
| | |
Director
|
| |
Chairman
|
| ||||||
Board of Directors
|
| | | | USD 50,000 | | | | | | USD 100,000 | | |
Board Committee
|
| | | | USD 15,000 | | | | | | USD 25,000 | | |
|
Seniority
|
| |
Entitlement effective as from
the date of employment |
|
|
More than 5 years
|
| |
Up to 2 months acclimatization
|
|
|
More than 10 years
|
| |
Up to 4 months acclimatization
|
|